Intellipharmaceutics International Inc., has announced the second quarter results for FY-2015~16. The results shows fall in Revenues by 14.2% down to $1.27 Million YoY and EPS down by -$0.02 to -$0.06. The Company recorded net loss for the three months ended May 31, 2015 of $1.5 million or $0.06 per diluted common share, compared with a net […]
Earnings: IntelliPharmaCeutics Up Losses $IPCI Read More »
pSivida Corp., a leader in the development of sustained release drug delivery products for treating eye diseases, today announced positive top line results from a Phase II investigator-sponsored study of pSivida’s Medidur for uveitis affecting the posterior of the eye (posterior, intermediate and pan-uveitis). Eyes treated with Medidur experienced a significant improvement in visual acuity,
News: pSivida Shows Positive Results of Medidur Study $PSDV Read More »
Douglas Williams, Ph.D., will leave Biogen at the end of July to become CEO of as-yet unnamed start-up biotechnology company. Dr. Williams will be the first member of a new organization with potential in cancer diagnostics and therapy. Responsibility for Biogen Research and Development will be assumed by Alfred Sandrock, M.D., Ph.D., senior vice president
News: Douglas Williams Leaving Biogen $BIIB Read More »
Edwards Lifesciences Corporation, the global leader in the science of heart valves and hemodynamic monitoring, today announced that it has agreed to acquire CardiAQ Valve Technologies, Inc., a privately held company and developer of a trans catheter mitral valve replacement system. “CardiAQ is proud of our pioneering efforts in the early development of this transcatheter
News: Edwards to acquire CardiAQ $EW Read More »
Adamas Pharmaceuticals, Inc., has completed the recruitment of its Phase 3 EASE LID study. EASE LID is a confirmatory trial designed to evaluate the efficacy and safety of ADS-5102 for the treatment of levodopa-induced dyskinesia (LID), a motor complication associated with the treatment of Parkinson’s disease. “This important achievement brings us one step closer to our
News: Adamas Enrollment for Parkinson Study $ADMS Read More »
